Does tetanus-diphtheria-acellular pertussis vaccination interfere with serodiagnosis of pertussis infection?

Clinical and Vaccine Immunology

Volumn 19, Issue 6, 2012, Pages 875-880

  Pawloski, Lucia C ^a   Kirkland, Kathryn B ^b   Baughman, Andrew L ^a   Martin, Monte D ^a   Talbot, Elizabeth A ^b   Messonnier, Nancy E ^a   Tondella, Maria Lucia ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIPHTHERIA PERTUSSIS TETANUS VACCINE; IMMUNOGLOBULIN G; VIRUS ANTIBODY;

ADULT; AGED; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BORDETELLA PERTUSSIS; COHORT ANALYSIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HEALTH CARE PERSONNEL; HUMAN; IMMUNOLOGICAL TOLERANCE; PERTUSSIS; PRIORITY JOURNAL; REFERENCE VALUE; SERODIAGNOSIS;

ADULT; AGED; ANTITOXINS; COHORT STUDIES; DIPHTHERIA-TETANUS-ACELLULAR PERTUSSIS VACCINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOGLOBULIN G; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; SEROLOGIC TESTS; TIME FACTORS; VACCINATION; WHOOPING COUGH;

EID: 84861752391     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.05686-11     Document Type: Article

References (29)

1. Amanna IJ, Carlson NE, Slifka MK. 2007. Duration of humoral immunity to common viral and vaccine antigens. N. Engl. J. Med. 357:1903-1915. (Pubitemid 350074686)
2. Baughman AL, et al. 2004. Establishment of diagnostic cutoff points for levels of serum antibodies to pertussis toxin, filamentous hemagglutinin, and fimbriae in adolescents and adults in the United States. Clin. Diagn. Lab Immunol. 11:1045-1053. (Pubitemid 39540842)
3. Booy R, et al. 2010. A decennial booster dose of reduced antigen content diphtheria, tetanus, acellular pertussis vaccine (Boostrix) is immunogenic and well tolerated in adults. Vaccine 29:45-50.
4. Broder KR, et al. 2006. Preventing tetanus, diphtheria, and pertussis among adolescents: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccines recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recommend. Rep. 55(RR-3):1-34.
5. Dalby T, Petersen JW, Harboe ZB, Krogfelt KA. 2010. Antibody responses to pertussis toxin display different kinetics after clinical Bordetella pertussis infection than after vaccination with an acellular pertussis vaccine. J. Med. Microbiol. 59:1029-1036.
6. de Melker HE, et al. 2000. Specificity and sensitivity of high levels of immunoglobulin G antibodies against pertussis toxin in a single serum sample for diagnosis of infection with Bordetella pertussis. J. Clin. Microbiol. 38:800-806.
7. Edelman K, et al. 2007. Immunity to pertussis 5 years after booster immunization during adolescence. Clin. Infect. Dis. 44:1271-1277. (Pubitemid 46717287)
8. Efron B, Tibshirani RJ. 1998. An introduction to the bootstrap. Chapman & Hall/CRC, New York, NY.
9. Fraser C, et al. 2007. Modeling the long-term antibody response of a human papillomavirus (HPV) virus-like particle (VLP) type 16 prophylactic vaccine. Vaccine 25:4324-4333. (Pubitemid 46635934)
10. Guiso N, et al. 2011. What to do and what not to do in serological diagnosis of pertussis: recommendations from EU reference laboratories. Eur. J. Clin. Microbiol. Infect. Dis. 30:307-312.
11. Hahn G, Meeker WQ. 1991. Statistical intervals: a guide for practitioners. John Wiley & Sons, Inc., New York, NY.
12. Hornung RW, Reed LD. 1990. Estimation of average concentration in the presence of nondetectable values. Appl. Occup. Environ. Hyg. 5:46-51. (Pubitemid 20094575)
13. Kapasi A, et al. 2012. Comparative study of different sources of pertussis toxin (PT) as coating antigens in IgG anti-PT enzyme-linked immunosorbent assays. Clin. Vaccine Immunol. 19:64-72.
14. Katki HA, Engels EA, Rosenberg PS. 2005. Assessing uncertainty in reference intervals via tolerance intervals: application to a mixed model describing HIV infection. Stat. Med. 24:3185-3198. (Pubitemid 41489429)
15. Kirkland KB, Talbot EA, Decker MD, Edwards KM. 2009. Kinetics of pertussis immune responses to tetanus-diphtheria-acellular pertussis vaccine in health care personnel: implications for outbreak control. Clin. Infect. Dis. 49:584-587.
16. Kretsinger K, et al. 2006. Preventing tetanus, diphtheria, and pertussis among adults: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine recommendations of the Advisory Committee on Immunization Practices (ACIP) and recommendation of ACIP, supported by the Healthcare Infection Control Practices Advisory Committee (HICPAC), for use of Tdap among health-care personnel. MMWR Recommend. Rep. 55(RR-17):1-37.
17. Le T, et al. 2004. Immune responses and antibody decay after immunization of adolescents and adults with an acellular pertussis vaccine: the APERT study. J. Infect. Dis. 190:535-544. (Pubitemid 38982093)
18. Marchant CD, et al. 1994. Pertussis in Massachusetts, 1981-1991: incidence, serologic diagnosis, and vaccine effectiveness. J. Infect. Dis. 169:1297-1305. (Pubitemid 24164594)
19. Menzies SL, et al. 2009. Development and analytical validation of an immunoassay for quantifying serum anti-pertussis toxin antibodies resulting from Bordetella pertussis infection. Clin. Vaccine Immunol. 16:1781-1788.
20. Mertsola J, et al. 2010. Decennial administration of a reduced antigen content diphtheria and tetanus toxoids and acellular pertussis vaccine in young adults. Clin. Infect. Dis. 51:656-662.
21. Rieber N, et al. 2008. Differences of humoral and cellular immune response to an acellular pertussis booster in adolescents with a whole cell or acellular primary vaccination. Vaccine 26:6929-6935.
22. Riffelmann M, Littmann M, Hulsse C, von Konig CH. 2009. Antibody decay after immunisation of health-care workers with an acellular pertussis vaccine. Eur. J. Clin. Microbiol. Infect. Dis. 28:275-279.
23. Riffelmann M, Thiel K, Schmetz J, Wirsing von Koenig CH. 2010. Performance of commercial enzyme-linked immunosorbent assays for detection of antibodies to Bordetella pertussis. J. Clin. Microbiol. 48:4459-4463.
24. SAS Institute, Inc. 2009. The mixed procedure. SAS/STAT 9.2 user's guide, second ed. SAS Institute, Inc., Cary, NC.
25. SAS Institute, Inc. 2010. The NLP procedure. SAS/OR 9.22 user's guide: mathematical programming. SAS Institute, Inc., Cary, NC.
26. Tondella ML, et al. 2009. International Bordetella pertussis assay standardization and harmonization meeting report. Centers for Disease Control and Prevention, Atlanta, Georgia, United States, 19-20 July 2007. Vaccine 27:803-814.
27. Watanabe M, Connelly B, Weiss AA. 2006. Characterization of serological responses to pertussis. Clin. Vaccine Immunol. 13:341-348.
28. Weston W, Messier M, Friedland LR, Wu X, Howe B. 2011. Persistence of antibodies 3 years after booster vaccination of adults with combined acellular pertussis, diphtheria and tetanus toxoids vaccine. Vaccine 29:8483-8486.
29. Xing D, et al. 2009. Characterization of reference materials for human antiserum to pertussis antigens by an international collaborative study. Clin. Vaccine Immunol. 16:303-311.